Navigation Links
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Date:7/24/2008

TITUSVILLE, N.J., July 24 /PRNewswire/ -- Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX(R) (topiramate), based on studies submitted in response to a Written Request by the FDA to investigate the use of TOPAMAX in pediatric patients aged 1 to 24 months with partial onset seizures.

In addition to granting pediatric exclusivity, the FDA is continuing its review of the application to determine the safety and efficacy of TOPAMAX in this patient population. Based on the data submitted, no indication is sought for this age group.

A recent court decision confirmed the validity of the TOPAMAX patent, which is set to expire in September 2008. However, this grant will extend the period of exclusivity through March 2009. TOPAMAX is not approved for use in pediatric patients aged 1 to 24 months.

TOPAMAX(R) is indicated as initial monotherapy in patients 10 years of age and older with partial onset seizures or generalized tonic-clonic seizures. It also is indicated as adjunctive therapy for adults and children (aged two and above) with partial onset seizures or generalized tonic-clonic seizures, and in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome. TOPAMAX(R) is indicated in adults for the prophylaxis of migraine headache.

Important Safety Information: Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.

Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.

More common side effects are tingling in arms and legs, loss of appetite, tiredness, nausea, diarrhea, taste change and weight loss.

Headquartered in Titusville, NJ, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., focuses exclusively on providing solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to explore new opportunities to develop solutions for unmet health care needs in neurology.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Wis. , March 27, 2017  A recent ... of only four freestanding hospitals in the country dedicated ... plastic and reconstructive surgery, concluded that the Surfacide Helios ... and integral component in reducing bacterial pathogens not killed ... findings were published at the American Burn Association,s 49th ...
(Date:3/27/2017)... -- To mark the end of Save Your Vision Month, ... digital imaging solutions, will showcase Canon eye care devices during ... New York,s Jacob Javits Center from March 30 ... the American Optometric Association, is observed annually in March to ... exams. In recognition of this observance, Canon U.S.A. ...
Breaking Medicine Technology:
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn placements ... channels. , While many results are clear, much of PR is hard to quantify. ... it comes to measurement, firms should always take an all-inclusive approach that takes both ...
(Date:3/28/2017)... ... , ... Thank you to all who attended Capio Partners Winter 2017 Healthcare ... exclusive to providers and offered an opportunity to collaborate and network with healthcare colleagues ... Hyatt where attendees gathered for a lively discussion on trends and issues that healthcare ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental team at ... teeth without the extensive time commitment and aesthetic disadvantages of traditional braces can ... A custom-designed series of virtually invisible aligners are created for each patient and ...
Breaking Medicine News(10 mins):